IVIG and PLEX in the treatment of myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 1-6

  Bril, Vera ^a   Barnett Tapia, Carolina ^a   Barth, David ^a   Katzberg, Hans D ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Comparison; Intravenous immunoglobulin; Myasthenia gravis; Plasma exchange; Plasmapheresis; Treatment

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE;

ANTIBODY TITER; ARTICLE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PATIENT SAFETY; PLASMAPHERESIS; QUALITY OF LIFE; QUANTITATIVE MYASTHENIA GRAVIS SCORE; TREATMENT RESPONSE;

EID: 84871580264     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06767.x     Document Type: Article

References (36)

1. Vincent, A., J. McConville, M.E. Farrugia, et al. 2003. Antibodies in myasthenia gravis and related disorders. Ann. N. Y. Acad. Sci. 998: 324-335.
2. Vincent, A., J. Palace & D. Hilton-Jones. 2001. Myasthenia gravis. Lancet 357: 2122-2128.
3. Vincent, A. & M.I. Leite. 2005. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18: 519-525.
4. Hohlfeld, R. & H. Wekerle. 1999. The Immunopathogenesis of myasthenia gravis. In Myasthenia Gravis and Myasthenic Disorders. A.G. Engel, Ed.: 87-104. Oxford University Press. New York.
5. Gajdos, P., S. Chevret & K. Toyka. 2002. Plasma exchange for myasthenia gravis. Cochrane. Database Syst. Rev. CD002275.
6. Lisak, R.P. 1984. Plasma exchange in neurologic diseases. Arch. Neurol. 41: 654-657.
7. Keesey, J.C. 2004. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29: 484-505.
8. Cortese, I., V. Chaudhry, Y.T. So, et al. 2011. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76: 294-300.
9. Zinman, L., E. Ng & V. Bril. 2007. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68: 837-841.
10. Miller, R.G., R.J. Barohn & R. Dubinsky. 2010. Expanding the evidence base for therapeutics in myasthenia gravis. Ann. Neurol. 68: 776-777.
11. Gajdos, P., S. Chevret & K. Toyka. 2008. Intravenous immunoglobulin for myasthenia gravis. Cochrane. Database Syst. Rev. CD002277.
12. Patwa, H.S., V. Chaudhry, H. Katzberg, et al. 2012. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78: 1009-1015.
13. Mandawat, A., H.J. Kaminski, G. Cutter, et al. 2010. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurol. 68: 797-805.
14. Gajdos, P., S. Chevret, B. Clair, et al. 1997. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41: 789-796.
15. Stricker, R.B., B.J. Kwiatkowska, J.A. Habis & D.D. Kiprov. 1993. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch. Neurol. 50: 837-840.
16. Barth, D., M. Nabavi Nouri, E. Ng, et al. 2011. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76: 2017-2023.
17. Ephrem, A., S. Chamat, C. Miquel, et al. 2008. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
18. Soueidan, S.A. & M.C. Dalakas. 1993. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr. Res. 33: S95-S100.
19. Anthony, R.M., F. Wermeling, M.C. Karlsson & J.V. Ravetch. 2008. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105: 19571-19578.
20. Jensen, P. & V. Bril. 2008. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J. Clin. Neuromuscul. Dis. 9: 352-355.
21. Dau, P.C. 1983. Immune globulin intravenous replacement after plasma exchange. J. Clin. Apher. 1: 104-108.
22. Fateh-Moghadam, A., M. Wick, U. Besinger & R.G. Geursen. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1: 848-849.
23. Pinching, A.J. & D.K. Peters. 1976. Remission of myasthenia gravis following plasma-exchange. Lancet 2: 1373-1376.
24. Skeie, G.O., S. Apostolski, A. Evoli, et al. 2010. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17: 893-902.
25. Qureshi, A.I., M.A. Choudhry, M.S. Akbar, et al. 1999. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52: 629-632.
26. Tindall, R.S., J.T. Phillips, J.A. Rollins, et al. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N. Y. Acad. Sci. 681: 539-551.
27. Ebadi, H., D. Barth & V. Bril. In Press. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve.
28. Norda, R., B.G. Stegmayr, Swedish Apheresis Group. 2003. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus. Apher. Sci. 29: 159-166.
29. Mullins, L.L., M.Y. Carpentier, R.H. Paul & D.B. Sanders. 2008. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 38: 947-956.
30. Barnett, C., G. Wilson, D. Barth, et al. In Press. Changes in MG-QOL with IVIG or plasmapheresis in patients with myasthenia gravis. J. Neurol. Neurosurg. Psychiatry.
31. Jaretzki, A. 3rd, R.J. Barohn, R.M. Ernstoff, et al. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann. Thorac. Surg. 70: 327-334.
32. Sanders, D.B., I.K. Hart, R. Mantegazza, et al. 2008. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71: 400-406.
33. Barnett, C., H. Katzberg, M. Nabavi & V. Bril. 2012. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological & laboratory markers. J. Clin. Neuromuscul. Dis. 13: 201-205.
34. Zinman, L., D. Baryshnik & V. Bril. 2008. Surrogate therapeutic outcome measures in patients with myasthenia gravis. Muscle Nerve 37: 172-176.
35. Katzberg, H.D., C. Barnett & V. Bril. 2012. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve 45: 648-652.
36. Barnett, C., Y. Grinberg, M. Ghani, et al. 2012. Fcgamma receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis. J. Clin. Neuromuscular. Dis. 14: 1-6.